Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
Status:
Recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
Soft tissue sarcoma (STS) is a relatively rare type of malignant tumor with an incidence of
1-2/100000. For unresectable or widely disseminated advanced STS, a combined clinical trial
is the best way to obtain evidence-based medical evidence.
Anlotinib, a multi-target receptor tyrosine kinase inhibitor (TKI), is effective for various
histological types of STS and the safety is tolerable. TKIs may reverse drug resistance or
inefficiency of immunoassay inhibitors, and combination therapy has shown preliminary
efficacy in a variety of tumors.
Because of the poor prognosis of refractory and advanced STS, there is no standard
second-line treatment. Therefore, combined therapies based on the original targeted drugs
would be paid more concentrations in the future. We focus on exploring the feasibility of
combination of anlotinib and Toripalimab monoclonal antibody in advanced, refractory and
progressive soft tissue sarcoma after failure of standard treatment, and look forward to
further improving the efficacy of soft tissue sarcoma.